Precigen Executive Compensation (FY25)

Name: Precigen (PGEN) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

PGEN · Executive and director compensation, fiscal 2023 to 2025

The Precigen brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $1,200 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

Data as of September 7, 2026Latest filing (8-K): June 24, 2026

14 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Precigen brief$1,500Get the executive brief

255 figures on this page: 244 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

Chief executive, fiscal 2025

◇

Helen Sabzevari

Latest say-on-pay support

June 24, 2026

Chief executive pay ratio

◇

To the median employee

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive total compensation — Helen Sabzevari: $5,431,895 → $5,354,329 (1.4% lower)

CEO pay ratio: 35:1 → 34:1 (2.9% lower)

Frequently asked questions

Answers drawn from the data on this page.

Who is Precigen's chief executive and what were they paid?

Helen Sabzevari, President and Chief Executive Officer, received $5,354,329 in total compensation for fiscal 2025. Compared with the $5,431,895 reported for fiscal 2024, Sabzevari's total was 1.4% lower.

What was Precigen's say-on-pay result?

Shareholders supported the say-on-pay proposal with 98.7% of votes cast for or against in favor at the meeting held June 24, 2026 for fiscal 2025.

Which companies are in Precigen's peer group?

Companies named in the disclosed peer group include Aura Bioscience, Day One Biopharmaceuticals, Kyverna Therapeutics, Replimune Group and Rocket Pharmaceuticals.

What is Precigen's chief executive pay ratio?

For fiscal 2025, the company reported a chief executive pay ratio of 34:1, against median employee compensation of $159,500.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Helen Sabzevari President and Chief Executive Officer	◇	—	◇	◇	—	—	◇	◇
Harry Thomasian Jr. Chief Financial Officer	◇	—	◇	◇	—	—	◇	◇
Donald Lehr Chief Legal Officer	◇	—	◇	◇	—	—	◇	◇
Rutul Shah Chief Operating Officer	◇	—	◇	◇	—	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Helen Sabzevari President and Chief Executive Officer	◇	—	◇	◇	—	—	◇	◇
Rutul Shah Chief Operating Officer	◇	—	◇	◇	—	—	◇	◇
Harry Thomasian Jr. Chief Financial Officer	◇	—	◇	◇	—	—	◇	◇
Donald Lehr Chief Legal Officer	◇	—	◇	◇	—	—	◇	◇
Phil Tennant Chief Commercial Officer	◇	—	◇	◇	—	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Helen Sabzevari President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Rutul Shah Chief Operating Officer	◇	—	◇	◇	◇	—	◇	◇
Harry Thomasian Jr. Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇
Donald Lehr Chief Legal Officer	◇	—	◇	◇	◇	—	◇	◇
Phil Tennant Chief Commercial Officer	◇	—	◇	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Donald P. Lehr	RSU	◇	—	—	◇	—	—	◇
Donald P. Lehr	RSU	◇	—	—	◇	—	—	◇
Donald P. Lehr	OPTION	◇	—	—	◇	—	◇	◇
Harry Thomasian Jr	OPTION	◇	—	—	◇	—	◇	◇
Harry Thomasian Jr	RSU	◇	—	—	◇	—	—	◇
Harry Thomasian Jr	RSU	◇	—	—	◇	—	—	◇
Helen Sabzevari	RSU	◇	—	—	◇	—	—	◇
Helen Sabzevari	OPTION	◇	—	—	◇	—	◇	◇
Helen Sabzevari	RSU	◇	—	—	◇	—	—	◇
Phil Tennant	RSU	◇	—	—	◇	—	—	◇
Phil Tennant	OPTION	◇	—	—	◇	—	◇	◇
Phil Tennant	RSU	◇	—	—	◇	—	—	◇
Rutul R. Shah	RSU	◇	—	—	◇	—	—	◇
Rutul R. Shah	OPTION	◇	—	—	◇	—	◇	◇
Rutul R. Shah	RSU	◇	—	—	◇	—	—	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Helen Sabzevari	Option	◇	—	◇	2/2/2032
	Option	◇	—	◇	4/28/2033
	RSU	◇	◇	—	—
	Option	◇	—	◇	5/31/2034
	Option	◇	—	◇	5/23/2035
Rutul Shah	Option	◇	—	◇	4/28/2033
	Option	◇	—	◇	5/31/2034
	RSU	◇	◇	—	—
	Option	◇	—	◇	5/23/2035
	Option	◇	—	◇	2/2/2032
Harry Thomasian	Option	◇	—	◇	5/23/2035
	RSU	◇	◇	—	—
	Option	◇	—	◇	2/2/2032
	Option	◇	—	◇	4/28/2033
	Option	◇	—	◇	5/31/2034
Phil Tennant	RSU	◇	◇	—	—
	Option	◇	—	◇	5/23/2035
	Option	◇	—	◇	7/22/2034
Donald Lehr	RSU	◇	◇	—	—
	Option	◇	—	◇	5/31/2034
	Option	◇	—	◇	5/23/2035
	Option	◇	—	◇	2/2/2032
	Option	◇	—	◇	4/28/2033

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Randal Kirk Board chair	◇	◇	◇	—	—	—	◇
Jeffrey Kindler	◇	◇	◇	—	—	—	◇
Vinita Gupta	◇	◇	◇	—	—	—	◇
Fred Hassan	◇	◇	◇	—	—	—	◇
James Turley Lead independent director	◇	◇	◇	—	—	—	◇
Cesar Alvarez	◇	◇	◇	—	—	—	◇
Nancy Howell Agee	◇	◇	◇	—	—	—	◇
Steven Frank	◇	◇	◇	—	—	—	◇

Helen Sabzevari served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Compensation committee chair	◇

Equity is delivered as Options and RSUs.

Stock ownership guideline: 5x annual cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Aura Bioscience AURA
Day One Biopharmaceuticals DAWN
Kyverna Therapeutics KYTX
Replimune Group REPL
Rocket Pharmaceuticals RCKT

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	June 24, 2026	=	◇	◇	◇
2024	June 30, 2025	=	◇	◇	◇
2023	July 5, 2024	=	◇	◇	◇
2022	June 8, 2023	=	◇	◇	◇
2021	June 9, 2022	=	◇	◇	◇
2020	June 10, 2021	=	◇	◇	◇
2019	June 19, 2020	=	◇	◇	◇
2018	June 12, 2019	=	◇	◇	◇
2017	June 7, 2018	=	◇	◇	◇
2016	June 28, 2017	=	◇	◇	◇
2015	June 9, 2016	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

What this page does not include

Everything above is a fact Precigen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Precigen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $1,200

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

255 figures on this page: 244 cited to the filing that reported them, 11 calculated from figures it prints.

244 cited to the filing

11 calculated from the filing

Documents cited

8-K, filed June 24, 2026
0000950103-26-009441
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 30, 2026
0001140361-26-018214
CEO PAY RATIO · Director Compensation Table for 2025 · GRANTS OF PLAN-BASED AWARDS FOR 2025 · Non-Employee Director Compensation · and 2 more sections
8-K, filed June 30, 2025
0000950103-25-008124
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed May 16, 2025
0001140361-25-019470
Summary Compensation Table
8-K, filed July 5, 2024
0000950103-24-009693
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed May 28, 2024
0001104659-24-065631
Summary Compensation Table
8-K, filed June 9, 2023
0000950103-23-008709
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 14, 2022
0000950103-22-010571
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 15, 2021
0000950103-21-008832
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 19, 2020
0001193125-20-174055
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 12, 2019
0001193125-19-171376
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 8, 2018
0001193125-18-187136
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 30, 2017
0001193125-17-220231
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 13, 2016
0001193125-16-620186
Item 5.07 Submission of Matters to a Vote of Security Holders

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Precigen executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/PGEN (accessed 2026).

Short form: data: Velarion

The Precigen brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $1,200 for the board report; $2,400 for both.

Get the executive brief Get the board briefNo account needed.

14 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/PGEN/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Precigen executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Precigen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Peers Precigen discloses

The companies named in PGEN's own disclosed peer group.

Aura Bioscience Day One Biopharmaceuticals Kyverna Therapeutics Replimune Group Rocket Pharmaceuticals

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}